MAB4130
Anti-Thymidylate Synthase Antibody, clone TS106
clone TS106, Chemicon®, from mouse
Synonym(s):
Thymidylate synthase
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
clone
TS106, monoclonal
species reactivity
human, mouse
species reactivity (predicted by homology)
rat
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
flow cytometry: suitable
immunofluorescence: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
General description
TS (EC:2.1.1.45), a cytosolic enzyme, is a dimmer of two identical monomers of about 36kDa. The enzyme provides the sole intracellular de novo source of thymidylate and plays a crucial role in DNA replication and repair. TS catalyzes the methylation of deoxyuridine monophosphate (dump) and its conversion to deoxythymidine monophosphate (dTMP). Therefore, TS is primarily active in proliferating and metabolic active cells. TS is a central target of the widely used antineoplastic agent 5-Fluorouracil (5-FU) and thus also of the Xeloda, which is enzymatically activated to 5-FU. TS is inactivated by a covalent complex formation with 5-FdUMP and methylenetetrahydrofolate. Literature indicates that expression of TS is associated with response to 5-fluorouracil (5-FU) in human breast, colorectal, gastric, head, and neck carcinomas with low TS expression predicting better response to 5-FU and survival.
Specificity
Antibody MAB4130 recognizes a 36 kDa protein identified as Thymidylate Synthase [TS], which is a target for the fluoropyrimidine group of antineoplastic drugs used to treat solid tumors. Expression of TS is associated with response to 5-fluorouracil (5-FU) in human breast, colorectal, gastric, head, and neck carcinomas.
Immunogen
Recombinant Thymidylate Synthase.
Application
ELISA:
A previous lot of this antibody was used in ELISA.
Flow Cytometry:
A previous lot of this antibody was used in FC.
Immunofluorescence:
A previous lot of this antibody was used in IF.
Immunoprecipitation:
A 10 μL/mg concentration of a previous lot was used on protein lysate.
Immunohistochemistry (Frozen and Paraffin sections):
1:50 - 1:100 (with incubation for 30-60 minutes at room temperature). TS106 can benefit from antigen retrieval with either EDTA pH 8.0 or 10mM citrate buffer pH 6.0 .
Western Blotting:
1:200 - 1:400. Recognizes a 36KDa band.
Optimal working dilutions must be determined by end user.
A previous lot of this antibody was used in ELISA.
Flow Cytometry:
A previous lot of this antibody was used in FC.
Immunofluorescence:
A previous lot of this antibody was used in IF.
Immunoprecipitation:
A 10 μL/mg concentration of a previous lot was used on protein lysate.
Immunohistochemistry (Frozen and Paraffin sections):
1:50 - 1:100 (with incubation for 30-60 minutes at room temperature). TS106 can benefit from antigen retrieval with either EDTA pH 8.0 or 10mM citrate buffer pH 6.0 .
Western Blotting:
1:200 - 1:400. Recognizes a 36KDa band.
Optimal working dilutions must be determined by end user.
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Cell Cycle, DNA Replication & Repair
Cell Cycle, DNA Replication & Repair
Use Anti-Thymidylate Synthase Antibody, clone TS106 (Mouse Monoclonal Antibody) validated in ELISA, FC, IF, IHC, IHC(P), IP, WB to detect Thymidylate Synthase also known as Thymidylate synthase.
Quality
Evaluated by Western Blot on MCF7 lysates.
Western Blot Analysis:
1:500 dilution of this antibody detected THYMIDYLATE SYNTHASE on 10 μg of MCF7 lysates.
Western Blot Analysis:
1:500 dilution of this antibody detected THYMIDYLATE SYNTHASE on 10 μg of MCF7 lysates.
Target description
36 kDa
Physical form
Format: Purified
Protein A purified
Purified mouse monoclonal IgG1 in 0.02M PBS with 0.25M NaCl, pH=7.6, 0.1% sodium azide.
Storage and Stability
Stable for 1 year at 2-8ºC from date of receipt.
Analysis Note
Control
Positive Control: 5-FU-resistant colon carcinoma cell lines (NCI H630R10, NCI630R1), 5-FU-resistant breast cancer cell lines, MCF-Ad5 and MCF-Ad10
Positive Control: 5-FU-resistant colon carcinoma cell lines (NCI H630R10, NCI630R1), 5-FU-resistant breast cancer cell lines, MCF-Ad5 and MCF-Ad10
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage Class
10 - Combustible liquids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jeeyun Lee et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 14(1), 82-88 (2008-01-04)
There are no reliable prognostic markers that identify gastric cancer patients who may benefit from adjuvant chemoradiation therapy. E2F-1 was shown to be associated with radiosensitivity and chemosensitivity in certain tumor types. Therefore, we analyzed expression and prognostic significance of
Krzysztof Okoń et al.
Polish journal of pathology : official journal of the Polish Society of Pathologists, 57(1), 29-33 (2006-06-03)
Colorectal carcinoma is etiopathologically heterogenic. It may develop through a sequence of mutations leading to chromosome instability or be a result of defects in DNA repair mechanisms manifested by microsatellite instability. Carcinomas of this type are supposed to be characterized
K H Yeh et al.
British journal of cancer, 83(11), 1510-1515 (2000-11-15)
We have recently demonstrated that HDFL (high-dose 5-FU 2600 mg m-2 week-1 and leucovorin 500 mg m-2 week-1, weekly 24-h infusion) is highly active in the treatment of gastric cancer. To further clarify the possible mechanism underlying the improved activity
John G Yuen et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 30(11), 3450-3461 (2022-08-08)
MicroRNA (miRNAs) are pleiotropic post-transcriptional modulators of gene expression. Their inherently pleiotropic nature makes miRNAs strong candidates for the development of cancer therapeutics, yet despite their potential, there remains a challenge to deliver nucleic acid-based therapies into cancer cells. We
Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
Marisa Donada et al.
BMC gastroenterology, 13, 36-36 (2013-03-01)
There is uncertainty on the benefit of adjuvant chemotherapy in patients with stage II colorectal cancers. The aim of this study is to investigate the combined role of clinical, pathological and molecular parameters to identify those stage II patients who
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service